ClinicalTrials.gg

Program

EYE201

A development code. Also written as “MK-8748” and “Tiespectus”.

Its studies are mostly in Diabetic Retinopathy · Wet Macular Degeneration · Retinal Vein Occlusion, led by Merck.

Furthest: phase 3, since Feb 23, 20265 company-led studies, 4 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck54 open or runningphase 3since Feb 23, 2026Oct 28, 2024Jun 30, 2028phase 3 · NCT07440225
  • Named in Merck’s own pipeline as MK-8748, phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2024First study: phase 2 study in Retinal Vein OcclusionFirst studyNCT06664502 · 38 enrolled · United States, Puerto Rico
  2. Feb 23, 2026Phase 3 study in Macular DegenerationPhase 3 reachedNCT07440225 · 960 planned · United States, Argentina, Australia and more
  3. Mar 23, 2026Phase 3 study in Macular DegenerationNCT07496567 · 960 planned · United States, Brazil, Colombia and more
  4. Jul 10, 20262 phase 3 studies in Diabetic RetinopathyNCT07705607, NCT07705555

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Macular DegenerationNCT07440225
  2. Jul 31, 2028Primary completion: phase 3 study in Macular DegenerationNCT07496567
  3. Oct 31, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07705555
  4. Nov 30, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07705607

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07705607Diabetic Retinopathy · United States, Argentina, Israel and more3RecruitingNov 30, 20281,104
NCT07705555Diabetic Retinopathy · United States, Argentina, Australia and more3RecruitingOct 31, 2028960
NCT07496567Macular Degeneration · United States, Brazil, Colombia and more3RecruitingJul 31, 2028960
NCT07440225Macular Degeneration · United States, Argentina, Australia and more3RecruitingJun 30, 2028960
NCT06664502Retinal Vein Occlusion · United States, Puerto Rico2CompletedMar 25, 202638

How it is read

Names in the registry

  • “MK-8748”, 2 entries
  • “Tiespectus”, 2 entries
  • “EYE201”, 1 entry

Codes read as this program: MK8748, EYE201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.